Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support... see more

PINL:GRPOF - Post Discussion

Traxion Sab De Cv Ord Shs > What to expect from reborn trials
View:
Post by Golddetector on Aug 05, 2021 11:47pm

What to expect from reborn trials

Guys these are pain relief medication. The safety of the drug already assessed. It is patient has pain or not. As simple as that. My god is that so hard to understand. Did you guys even listen to latest interview with Guy? He is not willing to spend shareholders money on things that he is not sure about. That is after 6 weeks from dosing 1st patient and having multiple patients enrolled and expanding trials. So do you think QIXLEEF is not working? Some ppl here really.... no further comments.
Comment by new2mjstocks on Aug 06, 2021 12:24am
Where did you see multiple patients enrolled? How many of those are approved ? I do believe in this deal but pumping and bashing needs to stop let tetra do it work 
Comment by Golddetector on Aug 06, 2021 12:36am
Listen to last interview again Guy said that. Yes I'm very positive on tetra. I have been saying that even before starting my position. Information provided in my posts are from company web page and Guy interview. 
Comment by new2mjstocks on Aug 06, 2021 12:46am
Forget about Guy interview he's had several over many years let the facts speak. Let's not forget Sean interviews what happened to 30 60 90 days ?? What happened to patent being filed will blow this out ?? Let the TRIALS SPEAK 
Comment by Golddetector on Aug 06, 2021 12:53am
When ceo of tbp says he enrolled multiple patients. It is clear message that this done. Similar to the enrolment of 1st patient it was announced in the interview. It is different from I'm going to do so and so. 
Comment by DONOOW on Aug 06, 2021 9:23am
You are right only if the CEO Guy is not a big liar.
Comment by Davesnothere on Aug 06, 2021 9:57am
I am fairly confident, and would not be surprised , to see TBP trading permanently above $ 1.00 by year end 2021. Like $1.25 becomes the new place to be stuck while we wait for a deal with Big-Pharma. On the way to that number , I would expect a couple of Huge spikes while people cover short positions, bandwagon chasers jump on , and of course some prudent profit taking. jmho  Cheers !
Comment by new2mjstocks on Aug 06, 2021 10:13am
Finally a logical post thanks 
Comment by Bangada on Aug 06, 2021 11:44am
@Davesnothere But you would not be suprised either to see TBP continuously trading around 30 cents?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities